초록 ▼

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a su

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

대표청구항 ▼

What is claimed is: 1. An in vitro method for identifying a chemical compound that directly enhances binding of an FKBP12.6 binding protein (FKBP12.6) to a PKA-phosphorylated type 2 ryanodine receptor (RyR2), the method comprising: (a) exposing PKA-phosphorylated RyR2 to FKBP12.6, in the presence o

What is claimed is: 1. An in vitro method for identifying a chemical compound that directly enhances binding of an FKBP12.6 binding protein (FKBP12.6) to a PKA-phosphorylated type 2 ryanodine receptor (RyR2), the method comprising: (a) exposing PKA-phosphorylated RyR2 to FKBP12.6, in the presence or absence of a candidate chemical compound in vitro; (b) determining the amount of FKBP12.6 bound to PKA-phosphorylated RyR2 in the presence and absence of the compound, wherein an increased amount of FKBP12.6 bound to PKA-phosphorylated RyR2 in the presence of the compound indicates that the compound directly enhances binding of FKBP12.6 to PKA-phosphorylated RyR2; thereby (c) identifying the compound as a compound that directly enhances binding of FKBP12.6 bound to PKA-phosphorylated RyR2. 2. The method of claim 1, wherein the RyR2 is PKA-hyperphosphorylated. 3. The method of claim 1, wherein the PKA-phosphorylated RyR2 is immobilized to a solid phase. 4. The method of claim 3, wherein the solid phase is a plate or beads. 5. The method of claim 1, wherein the FKBP12.6 is radio-labeled. 6. The method of claim 5, wherein the FKBP12.6 is labeled with 35S. 7. The method of claim 1, wherein enhanced binding of PKA-phosphorylated RyR2 and FKBP12.6 is detected using an FKBP12.6-binding agent. 8. The method of claim 7, wherein the FKBP12.6-binding agent is an anti-FKBP12.6 antibody.